'Tectonic' Shifts In Germany’s OTC Market Require Smart Sales Strategies
Data from Sempora Consulting shows Germany's OTC market is still struggling to return to pre-pandemic growth levels in the first quarter of 2022. Digging deeper into recent trends like e-commerce and inflationary pricing, the firm suggests a number of points for consumer healthcare companies to consider in formulating their sales strategies for the rest of the year.
You may also be interested in...
Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.
The German Expert Committee for Prescription has rejected the Rx-to-OTC reclassifications of sildenafil (50mg) for oral use and xylometazoline and ipratropium bromide for intranasal use.
As Germany remains in lockdown, sales in its OTC market struggle to return to pre-pandemic levels, according to new data from Sempora Consulting. Meanwhile, COVID-related trends for wellness and online shopping endure, indicating some strategic priorities for OTC firms operating in the country.